Investor Overview

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through to Phase III in a cost-efficient manner.

Development programs are designed and driven by a leadership team that collectively has more than 75 years of experience in all areas of drug development. The Furiex model has proven success, with two compounds in Phase III development, one that is Phase III ready, and two products on the market.

Furiex Pharmaceuticals has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets.

Our strategy is to leverage our drug development experience to in-license, develop and commercialize novel early-stage drug candidates that address medical conditions with significant unmet medical need. The key elements of our strategy include:

  • Advance the clinical development of the current drug candidates in our pipeline. We plan to advance drug candidates based on the results of preclinical and clinical testing and assessment of market potential.

  • In-license or acquire additional early-stage compounds. The in-licensing of additional candidates in order to expand our portfolio and therefore increase long-term revenue opportunities is an objective of our company.

  • Establish strategic commercialization collaborations. We plan to develop and commercialize our drug candidates through partnering or licensing arrangements such as those with Menarini for Priligy® and Takeda for Nesina®. This strategy allows us to focus on our core development strengths and leverage the resources and commercialization capabilities already in place at our collaborators.

Investor Relations

Actavis Investor Relations
(862) 261-7488